In 180 adults who smoked and were switching to e-cigarettes, bupropion-zonisamide did not lower end-of-treatment exhaled CO versus bupropion or placebo (mITT); abstinence was 26.7%, 25.0% and 10.0%. Weight fell with the combination but rose with the others.
RCTn = 180
Rose et al. Combination bupropion-zonisamide facilitates rapid reduction in smoke exposure and prevents weight gain during switching to electronic nicotine delivery systems: A randomized clinical trial